Target family: Parathyroid hormone receptors (type: gpcr)
Target: PTH2 receptor

Ligand: [D-Trp12]PTH-(7-34) (bovine) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.3 pIC50
Reference (Journal): Regions in rat and human parathyroid hormone (PTH) 2 receptors controlling receptor interaction with PTH and with antagonist ligands.
Published in: J Pharmacol Exp Ther

Ligand: [D-Trp12]PTH-(7-34) (bovine) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6.3 pIC50
Reference (Journal): Regions in rat and human parathyroid hormone (PTH) 2 receptors controlling receptor interaction with PTH and with antagonist ligands.
Published in: J Pharmacol Exp Ther

Ligand: [D-Trp12,Tyr34]PTH-(7-34) (bovine) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6.9 pIC50
Reference (Journal): Tuberoinfundibular peptide (7-39) [TIP(7-39)], a novel, selective, high-affinity antagonist for the parathyroid hormone-1 receptor with no detectable agonist activity.
Published in: J Pharmacol Exp Ther

Ligand: [His4, Tyr5, Trp6, His7]TIP39 (human) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7.61 pA2

Ligand: [His5]PTH-(1-34) (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.6 pIC50
Reference (Journal): Converting parathyroid hormone-related peptide (PTHrP) into a potent PTH-2 receptor agonist.
Published in: J Biol Chem

Ligand: [Ile5]PTHrP-(1-36) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.2 pIC50
Reference (Journal): Regions in rat and human parathyroid hormone (PTH) 2 receptors controlling receptor interaction with PTH and with antagonist ligands.
Published in: J Pharmacol Exp Ther

Ligand: [Ile5,Trp23]PTHrP-(1-36) (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Studies of the N-terminal region of a parathyroid hormone-related peptide (1-36) analog: receptor subtype-selective agonists, antagonists, and photochemical cross-linking agents.
Published in: Endocrinology

Ligand: [Ile5,Trp23]PTHrP-(1-36) (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Converting parathyroid hormone-related peptide (PTHrP) into a potent PTH-2 receptor agonist.
Published in: J Biol Chem

Ligand: [Ile5,Trp23]PTHrP-(2-36) (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.3 pIC50
Reference (Journal): Studies of the N-terminal region of a parathyroid hormone-related peptide (1-36) analog: receptor subtype-selective agonists, antagonists, and photochemical cross-linking agents.
Published in: Endocrinology

Ligand: [Ile5,Trp23]PTHrP-(3-36) (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.2 pIC50
Reference (Journal): Studies of the N-terminal region of a parathyroid hormone-related peptide (1-36) analog: receptor subtype-selective agonists, antagonists, and photochemical cross-linking agents.
Published in: Endocrinology

Ligand: [Ile5,Trp23]PTHrP-(4-36) (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.8 pIC50
Reference (Journal): Studies of the N-terminal region of a parathyroid hormone-related peptide (1-36) analog: receptor subtype-selective agonists, antagonists, and photochemical cross-linking agents.
Published in: Endocrinology

Ligand: [Ile5,Trp23]PTHrP-(5-36) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 7 pIC50
Reference (Journal): Studies of the N-terminal region of a parathyroid hormone-related peptide (1-36) analog: receptor subtype-selective agonists, antagonists, and photochemical cross-linking agents.
Published in: Endocrinology

Ligand: [Ile5,Trp23]PTHrP-(5-36) (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7 pIC50
Reference (Journal): Studies of the N-terminal region of a parathyroid hormone-related peptide (1-36) analog: receptor subtype-selective agonists, antagonists, and photochemical cross-linking agents.
Published in: Endocrinology

Ligand: [Ile5,Trp23,Tyr36]PTHrP-(1-36)-NH2 (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.7 pIC50
Reference (Journal): Residues in the membrane-spanning and extracellular loop regions of the parathyroid hormone (PTH)-2 receptor determine signaling selectivity for PTH and PTH-related peptide.
Published in: J Biol Chem

Ligand: [Phe23]PTH-(1-34) (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.3 pIC50
Reference (Journal): Converting parathyroid hormone-related peptide (PTHrP) into a potent PTH-2 receptor agonist.
Published in: J Biol Chem

Ligand: PTH-(1-34) (rat) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Studies of the N-terminal region of a parathyroid hormone-related peptide (1-36) analog: receptor subtype-selective agonists, antagonists, and photochemical cross-linking agents.
Published in: Endocrinology

Ligand: PTH-(1-34) (rat) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Regions in rat and human parathyroid hormone (PTH) 2 receptors controlling receptor interaction with PTH and with antagonist ligands.
Published in: J Pharmacol Exp Ther

Ligand: PTH-(1-34) (rat) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Molecular determinants of tuberoinfundibular peptide of 39 residues (TIP39) selectivity for the parathyroid hormone-2 (PTH2) receptor. N-terminal truncation of TIP39 reverses PTH2 receptor/PTH1 receptor binding selectivity.
Published in: J Biol Chem

Ligand: PTH-(1-34) (rat) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.8 pIC50
Reference (Journal): Regions in rat and human parathyroid hormone (PTH) 2 receptors controlling receptor interaction with PTH and with antagonist ligands.
Published in: J Pharmacol Exp Ther

Ligand: PTHrP-(1-21)/PTH-(22-34) (human) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 5.5 pIC50
Reference (Journal): Regions in rat and human parathyroid hormone (PTH) 2 receptors controlling receptor interaction with PTH and with antagonist ligands.
Published in: J Pharmacol Exp Ther

Ligand: PTHrP-(1-21)/PTH-(22-34) (human) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Regions in rat and human parathyroid hormone (PTH) 2 receptors controlling receptor interaction with PTH and with antagonist ligands.
Published in: J Pharmacol Exp Ther

Ligand: PTHrP-(1-21)/PTH-(22-34) (human) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Converting parathyroid hormone-related peptide (PTHrP) into a potent PTH-2 receptor agonist.
Published in: J Biol Chem

Ligand: PTHrP-(1-34) (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 6.1 pIC50
Reference (Journal): Regions in rat and human parathyroid hormone (PTH) 2 receptors controlling receptor interaction with PTH and with antagonist ligands.
Published in: J Pharmacol Exp Ther

Ligand: PTHrP-(1-34) (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 5.3 pIC50
Reference (Journal): Regions in rat and human parathyroid hormone (PTH) 2 receptors controlling receptor interaction with PTH and with antagonist ligands.
Published in: J Pharmacol Exp Ther

Ligand: PTHrP-(1-36) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 5.7 pIC50
Reference (Journal): Converting parathyroid hormone-related peptide (PTHrP) into a potent PTH-2 receptor agonist.
Published in: J Biol Chem

Ligand: PTHrP-(7-34) (human, rat, mouse) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6.7 pIC50
Reference (Journal): Tuberoinfundibular peptide (7-39) [TIP(7-39)], a novel, selective, high-affinity antagonist for the parathyroid hormone-1 receptor with no detectable agonist activity.
Published in: J Pharmacol Exp Ther

Ligand: [125I][Nle8,21,Tyr34]PTH-(1-34)-NH2 (rat) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.1 pKd
Reference (Journal): Residues in the membrane-spanning and extracellular loop regions of the parathyroid hormone (PTH)-2 receptor determine signaling selectivity for PTH and PTH-related peptide.
Published in: J Biol Chem

Ligand: teriparatide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1987), EMA (2003)
Median affinity: 6.3 pIC50
Reference (Journal): Regions in rat and human parathyroid hormone (PTH) 2 receptors controlling receptor interaction with PTH and with antagonist ligands.
Published in: J Pharmacol Exp Ther

Ligand: teriparatide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1987), EMA (2003)
Median affinity:  pIC50
Reference (Journal): Converting parathyroid hormone-related peptide (PTHrP) into a potent PTH-2 receptor agonist.
Published in: J Biol Chem

Ligand: teriparatide (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: yes
Approval source: FDA (1987), EMA (2003)
Median affinity:  pIC50
Reference (Journal): Regions in rat and human parathyroid hormone (PTH) 2 receptors controlling receptor interaction with PTH and with antagonist ligands.
Published in: J Pharmacol Exp Ther

Ligand: TIP39 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Regions in rat and human parathyroid hormone (PTH) 2 receptors controlling receptor interaction with PTH and with antagonist ligands.
Published in: J Pharmacol Exp Ther

Ligand: TIP39 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.8 pIC50
Reference (Journal): Regions in rat and human parathyroid hormone (PTH) 2 receptors controlling receptor interaction with PTH and with antagonist ligands.
Published in: J Pharmacol Exp Ther

Ligand: TIP39 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 8.1 pIC50
Reference (Journal): Regions in rat and human parathyroid hormone (PTH) 2 receptors controlling receptor interaction with PTH and with antagonist ligands.
Published in: J Pharmacol Exp Ther

Ligand: TIP39 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7 pIC50
Reference (Journal): Regions in rat and human parathyroid hormone (PTH) 2 receptors controlling receptor interaction with PTH and with antagonist ligands.
Published in: J Pharmacol Exp Ther

Ligand: TIP39 (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Primary target: no
Median affinity:  pIC50
Reference (Journal): Molecular determinants of tuberoinfundibular peptide of 39 residues (TIP39) selectivity for the parathyroid hormone-2 (PTH2) receptor. N-terminal truncation of TIP39 reverses PTH2 receptor/PTH1 receptor binding selectivity.
Published in: J Biol Chem

Ligand: TIP39-(7-39) (human/bovine) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Tuberoinfundibular peptide (7-39) [TIP(7-39)], a novel, selective, high-affinity antagonist for the parathyroid hormone-1 receptor with no detectable agonist activity.
Published in: J Pharmacol Exp Ther

Ligand: TIP39-(7-39) (human/bovine) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6.1 pIC50
Reference (Journal): Regions in rat and human parathyroid hormone (PTH) 2 receptors controlling receptor interaction with PTH and with antagonist ligands.
Published in: J Pharmacol Exp Ther

Ligand: TIP39-(7-39) (human/bovine) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Regions in rat and human parathyroid hormone (PTH) 2 receptors controlling receptor interaction with PTH and with antagonist ligands.
Published in: J Pharmacol Exp Ther

Ligand: TIP39-(7-39) (mouse) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 6.5 pIC50
Reference (Journal): Regions in rat and human parathyroid hormone (PTH) 2 receptors controlling receptor interaction with PTH and with antagonist ligands.
Published in: J Pharmacol Exp Ther

Ligand: TIP39-(7-39) (mouse) (Peptide)
Interaction type: Antagonist
Action: Antagonist
Ligand approved: no
Median affinity: 8.2 pIC50
Reference (Journal): Regions in rat and human parathyroid hormone (PTH) 2 receptors controlling receptor interaction with PTH and with antagonist ligands.
Published in: J Pharmacol Exp Ther

Ligand: [Trp23]PTHrP-(1-36) (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.5 pIC50
Reference (Journal): Converting parathyroid hormone-related peptide (PTHrP) into a potent PTH-2 receptor agonist.
Published in: J Biol Chem

Ligand: [Trp23,Tyr36]PTHrP-(1-36)-NH2 (human) (Peptide)
Interaction type: Agonist
Action: Full agonist
Ligand approved: no
Median affinity: 7.4 pIC50
Reference (Journal): Residues in the membrane-spanning and extracellular loop regions of the parathyroid hormone (PTH)-2 receptor determine signaling selectivity for PTH and PTH-related peptide.
Published in: J Biol Chem